Slick, That’s not a bad post. It highlights how many investor's...

Slick,

That’s not a bad post. It highlights how many investor's and analysts have never actually had the experience of running a business, Their thinking is totally inflexible. They believe what they were once told at a specific point in time can’t change if a better idea or opportunity arises.

Thats why it’s important not to take much faith in experts.

Right from day one of this deal it was always about the Azer-Cell allogenic CarT therapy. It was never about a Wharehouse full of test tubes and Bunsen burners. Because of the very lengthy delays in the global manufacturing of cell therapies , this deal has enable IMU to get control of the supply lines contractually with out the headaches of running the factory.

So what could be playing out here is the market not understanding the business . Which causes mispricing the shares.

Where there is confusion there is profit. Don’t always assume the experts know what they are doing. Most of the time they don’t.